Hot on the heels of the Brenzys decision, the PBAC has been asked to relax prescribing requirements for a second biosimilar. Sponsor MSD Australia has asked the PBAC to use its new powers to recommend streamlined authority access to its inflixmab biosimilar Renflexis for patients who are continuing on the agent, or switching from any other bDMARD. ...
Second biosimilar heads down streamlined authority road
By Tessa Hoffman
22 Nov 2017